J&J begins clinical trial of single-dose coronavirus vaccine
Which biotech company will win the coronavirus vaccine race?
FOX Business’ Edward Lawrence reports on the Trump administration’s deal with companies like Fujifilm for the development of a coronavirus vaccine. Then, The Wall Street Journal editorial page deputy editor Dan Henninger discusses investing in biotech companies and the upcoming presidential election.
Johnson & Johnson announced Thursday that the first human clinical trials of its coronavirus vaccine candidate have begun in the U.S. and Belgium.
Continue Reading Below
MODERNA LAUNCHES PHASE 3 VACCINE TRIAL
"We are excited to see these pre-clinical data because they show our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose," Dr. Paul Stoffels, the company's chief scientific officer, said in a statement. "The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a Phase 1/2a trial in July with the intention to move into a Phase 3 trial in September."
|JNJ||JOHNSON & JOHNSON||146.54||-0.29||-0.20%|
Johnson & Johnson's trials will include "significant representation" of communities of color and the elderly, who have been disproportionately impacted by the virus, the company said.